Scott Boyken

Scott Boyken is co-founder and Chief Innovation Officer of Outpace Bio. During his postdoc in the Baker lab at the University of Washington, he pioneered new computational methods to design the first de novo proteins with programmable interaction specificity and moving parts, creating switches and logic gates capable of controlling new biological functions in cells. This work resulted in multiple high-impact publications and the Burroughs Wellcome Fund Career Award at the Scientific Interface. Based on this technology, he co-founded Lyell Immunopharma where he led a team creating new technologies to improve efficacy and safety for anti-cancer T cell therapies. Scott earned his PhD from Iowa State University where he was an NSF IGERT Fellow and his dissertation research combined biochemical assays with computational modeling to study kinase-mediated immune cell signaling. In 2021, Scott was selected for Endpoints 20 under 40. He has authored more than 30 scientific publications and is an inventor on 16 published patent families.